The 14th Canadian Symposium on Hepatitis C Virus: From research breakthroughs to equitable health care for priority populations.
Background: The hepatitis C virus (HCV) affects approximately 214,000 Canadians. While the availability of safe, effective direct-acting antivirals (DAA) has led to decreased rates of chronic HCV infection and increased treatment uptake, major challenges to achieving HCV elimination remain. This rep...
| Publicado en: | Canadian Liver Journal Vol. 8; no. 4; pp. 540 - 554 |
|---|---|
| Autores principales: | , , , , , , , , , , , , , , , |
| Formato: | Journal Article |
| Publicado: |
University of Toronto Press
Nov2025
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=189861348&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 189861348 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 25614444 M7KW jtl: Canadian Liver Journal issn: 25614444 maglogo: N pubinfo: dt: Nov2025 vid: 8 iid: 4 pid: 678 pub: University of Toronto Press place: North York, Ontario artinfo: ui: 189861348 10.3138/canlivj-2025-0034 189861348 ppf: 540 ppct: 14 formats: tig: atl: The 14th Canadian Symposium on Hepatitis C Virus: From research breakthroughs to equitable health care for priority populations. aug: au: Elakpa, Daniel N Lawton, David Tooley, Trinity H van Rooyen, Kerryn Bruneau, Julie Cooper, Curtis Dickie, Melisa Feld, Jordan J Janjua, Naveed Z King, Alexandra Kronfli, Nadine Presseau, Justin Wilson, Joyce Vachon, Marie-Louise Fontaine, Guillaume on Hepatitis C, on behalf of the Canadian Network affil: McGill University, Montreal, Quebec, Canada sug: subj: Congresses and Conferences Canada Hepatitis C Therapy Hepatitis C Prevention and Control Health Services Accessibility Multidisciplinary Care Team Canada Hepatitis Viruses Point-of-Care Testing Sex Factors Research, Medical Implementation Science ab: Background: The hepatitis C virus (HCV) affects approximately 214,000 Canadians. While the availability of safe, effective direct-acting antivirals (DAA) has led to decreased rates of chronic HCV infection and increased treatment uptake, major challenges to achieving HCV elimination remain. This report summarizes key findings from the 14th Canadian Symposium on Hepatitis C Virus, which focused on advancing equitable strategies for HCV elimination through multidisciplinary dialogue. Methods: The symposium was titled "From Research Breakthroughs to Equitable Healthcare for Priority Populations," and brought together researchers, clinicians, policymakers, and community stakeholders to advance Canada's efforts toward HCV elimination by 2030. Hosted in Quebec City by the Canadian Network on Hepatitis C (CanHepC), the symposium highlighted key findings across biomedical, clinical, population health, and health services research. Results: Biomedical presentations emphasized progress in HCV vaccine development, host-virus interactions, and T-cell exhaustion mechanisms. Notable findings included novel insights into immune escape pathways, host-targeted antivirals, and epigenetic barriers to T-cell reinvigoration. Clinical and population health sessions addressed inequities in HCV prevention and care for women and pregnant people, incarcerated individuals, and people who use drugs. Presenters showcased the impact of decentralized point-of-care HCV RNA testing on diagnosis and linkage to treatment in high-risk populations, including those with unstable housing. Implementation-focused discussions included updates to the national Blueprint to Inform HCV Elimination and strategies to scale nurse-led and community-based interventions. Conclusions: The symposium emphasized the importance of integrating scientific advances with community-driven and equity-focused actions, particularly for priority populations experiencing systemic barriers to care. Through inclusive dialogue and multidisciplinary knowledge exchange, the symposium reaffirmed CanHepC's commitment to bridging research and practice to accelerate the path toward HCV elimination in Canada. Lay Summary: Hepatitis C is a virus that affects about 214,000 people in Canada. Thanks to new medications called direct-acting antivirals, more people are being cured, and the number of infections is going down. However, there are still serious challenges in ensuring that everyone, especially those most affected, can be tested, treated, and cured. The 14th Canadian Symposium on Hepatitis C Virus, hosted by the Canadian Network on Hepatitis C, brought together researchers, health care providers, community leaders, and people with lived experience to share the latest research findings. The event focused on how to close gaps in care and improve health equity. The presenters shared research on developing a vaccine for hepatitis C, understanding how the virus hides from the immune system, and how to design better treatments. Others focused on the real-world challenges people face when trying to be tested and treated, especially pregnant women, people in prison, and people who use drugs. A major theme was the importance of bringing health care services to where people are, such as offering rapid, on-the-spot hepatitis C testing in community settings. Discussions also highlighted how nurse- and peer-led programs can build trust and improve care. Overall, the symposium showed that while medical advances are important, eliminating hepatitis C in Canada also requires community engagement, reducing stigma, and making care more accessible for everyone. pubtype: Academic Journal doctype: Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|